Welcome to our dedicated page for Smith & Nephew plc news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew plc stock.
Smith & Nephew plc, also known as Smith+Nephew, is a leading British multinational medical equipment manufacturing company headquartered in Watford, England. Established in 1856, this pioneering firm excels in designing, manufacturing, and marketing advanced medical devices and technologies. Their core business areas include orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.
Smith+Nephew's revenue is diversified across three main segments: Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%). The United States contributes roughly half of the company’s total revenue, with other developed markets accounting for over 30%, and the remaining portion coming from emerging markets. The company operates in more than 100 countries and generated annual sales of $5.2 billion in 2022.
Recently, Smith+Nephew celebrated a significant milestone by receiving 510(k) clearance from the U.S. FDA for the AETOS Shoulder System. This advanced system is designed to enhance surgical experiences through greater intraoperative flexibility and fewer conversion steps and instruments, simplifying the operating room flow. The AETOS Shoulder System is part of the company's expanding Upper Extremity portfolio and complements its market-leading Sports Medicine shoulder repair and biologics solutions.
Another notable achievement includes the standout results of the REGENETEN Bioinductive Implant from a randomized controlled trial. This innovative implant substantially reduced re-tear rates in rotator cuff repairs, showcasing Smith+Nephew's commitment to improving patient outcomes through evidence-based solutions.
Smith+Nephew has also entered into a groundbreaking Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This agreement allows for collaborative research across all business units, fostering innovation and enhancing combat casualty care.
Moreover, the company launched the RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US, which is a patient-centric option for treating chronic wounds. This system is designed for easy portability and quiet operation, making it suitable for patients' daily activities.
Smith+Nephew's purpose, 'Life Unlimited,' reflects their mission to help restore people's bodies and self-belief by using technology to enhance living. With 19,000 dedicated employees, the company continues to innovate and improve the quality of life for patients worldwide.
For more information about Smith+Nephew, please visit their official website and follow them on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Smith+Nephew (NYSE:SNN) has launched the WOUND COMPASS™ Clinical Support App, aimed at assisting healthcare professionals in wound assessment and decision-making. The app addresses practice variation, which negatively affects patient outcomes in chronic wound care. Validated by over 70 clinicians, it enhances nurse confidence in assessments, with 83% of non-specialists reporting it simplifies evaluations. Available on both Apple and Android, the app categorizes wounds and offers tailored treatment guidance. This innovation is part of Smith+Nephew’s commitment to improving patient care and outcomes.
Smith+Nephew (NYSE: SNN) successfully performed its first robotic-assisted surgery using the LEGION CONCELOC Cementless Total Knee System. Conducted by Dr. Cyna Khalily in Louisville, KY, this milestone enhances its portfolio of cementless knee implants and robotic technology. The procedure employs the CORI Surgical System, designed to optimize surgical efficiency by eliminating preoperative CT imaging, thus reducing costs and radiation exposure. This innovation reflects Smith+Nephew's commitment to improving surgical outcomes and employing advanced materials for knee arthroplasty.
Smith+Nephew (LSE: SN, NYSE: SNN) published a peer-reviewed article in Wounds International predicting a potential release of 3.5 billion hours of nursing time by 2030 through shared care in chronic wound management and the use of long-wear advanced foam dressings. The study highlights a global nursing shortage of 10.6 million by 2030, emphasizing the need for efficient care practices. The implementation of shared care practices could lead to an annual reallocation of over 433 million hours of clinical nursing time worldwide, enhancing patient care and optimizing resources.
Smith+Nephew (NYSE:SNN) announced the successful first total hip arthroplasty (THA) using its RI.HIP MODELER at Duke Regional Hospital. The procedure was performed by Dr. Rhett Hallows, who utilized the preoperative spinopelvic assessment tool to enhance surgical planning. In April, Dr. Thorsten Seyler executed the inaugural RI.HIP NAVIGATION procedure on the CORI Surgical System. This system aids in precise component alignment, addressing challenges in hip surgery. The innovations are expected to drive growth for the CORI Surgical System.
Healiva® announced its acquisition of two innovative cell therapy assets from Smith+Nephew (NYSE:SNN), enhancing its portfolio of chronic wound care solutions. The first asset, EpiDex®, is an autologous epidermal equivalent that facilitates surgery-free healing for chronic venous leg ulcers (VLUs), while the second, healiva®002, is an allogeneic cell therapy proven effective for hard-to-treat VLUs. This acquisition aims to expedite market launch and addresses the urgent need for effective treatments for the 36 million people suffering from chronic wounds worldwide.
Smith+Nephew (LSE: SN, NYSE: SNN) announced a peer-reviewed study published in the Advances in Wound Care Journal, demonstrating that GRAFIX Cryopreserved Placental Membrane significantly cuts diabetic foot ulcer (DFU) recurrence rates. The study analyzed over 1.3 million Medicare patients and showed a reduction of up to 58.5% in ulcer recurrence at 365 days compared to competitors. With Medicare patients spending an estimated $6-18 billion annually on DFU treatment, GRAFIX has gained coverage from Medicare and major payers, reinforcing its potential financial advantage.
Smith+Nephew (NYSE:SNN) will showcase its innovations in Orthopaedic Reconstruction and Robotics at the AAOS 2022 Annual Meeting in Chicago. The highlight is the launch of the LEGION CONCELOC Cementless Total Knee System, marking Smith+Nephew as the only U.S. company with a complete cementless knee portfolio. Their ABLE Advanced Anterior Approach for Total Hip Arthroplasty is also noteworthy for its efficiency and low complication rates. The CORI Surgical System, offering expanded indications in orthopedic procedures, will also be presented, enhancing Smith+Nephew's robotic-assisted surgery capabilities.
Smith+Nephew (LSE:SN, NYSE:SNN) announced the showcase of its latest Sports Medicine innovations at the American Academy of Orthopaedic Surgeons 2022 Annual Meeting in Chicago, IL. Key products include the FAST-FIX™ FLEX Meniscal Repair System, which enhances meniscus repair opportunities, and the INTELLIO™ Connected Tower, which integrates surgical technologies for improved workflow. Other innovations include the WEREWOLF™ FASTSEAL 6.0 Hemostasis Wand and REGENETEN™ Bioinductive Implant, aimed at better patient outcomes and efficiency in joint surgeries.
Smith+Nephew (LSE: SN, NYSE: SNN) has launched the OXINIUM Technology Tour of Change, a 550-square-foot mobile exhibit covering 20 U.S. cities over 12 weeks. This initiative showcases OXINIUM Technology, recognized for its low revision risk in total hip arthroplasty, with over two million clinical cases. The exhibit aims to educate healthcare professionals on the unique manufacturing of OXINIUM, emphasizing its durability, wear resistance, and absence of harmful nickel, cobalt, and chromium. The tour also highlights OXINIUM's integration with Smith+Nephew's Real Intelligence platform.
Smith+Nephew (NYSE:SNN) announced the successful completion of the first surgery using its JOURNEY II Medial Dished (MD) System for total knee arthroplasty (TKA). Performed by Dr. Ran Schwarzkopf at NYU Langone Health, this innovative system enhances knee kinematics and stability. The JOURNEY II MD aims to improve patient outcomes and satisfaction by replicating natural motion in knee replacements. The product is now available in the United States, following customer demand for medial dished inserts that expand clinical applications of the JOURNEY II Knee System.
FAQ
What is the current stock price of Smith & Nephew plc (SNN)?
What is the market cap of Smith & Nephew plc (SNN)?
What does Smith & Nephew specialize in?
Where is Smith & Nephew headquartered?
What are the main revenue segments of Smith & Nephew?
What recent achievement has Smith & Nephew made in orthopedic technology?
How does the REGENETEN Bioinductive Implant benefit patients?
What is the purpose of Smith & Nephew's Master CRADA with the USAISR?
What is unique about the RENASYS EDGE NPWT System?
What is Smith & Nephew's company mission?
How many countries does Smith & Nephew operate in?
How can I learn more about Smith & Nephew?
